Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The DRC is receiving 70,000 doses of the Ervebo Ebola vaccine to combat an active Bundibugyo virus outbreak — but whether it works against this strain remains unknown. WHO and Africa CDC are backing the move, which includes a Phase 3 trial to find out. It's a calculated bet to save lives while generating critical scientific evidence.
The Democratic Republic of the Congo (DRC) is receiving an emergency allocation of 70,000 doses of Ervebo — the licensed Ebola vaccine — to respond to an ongoing Bundibugyo virus disease outbreak. The release was approved by the International Coordinating Group (ICG) on Vaccine Provision, which manages the global Ebola vaccine stockpile. Both WHO and Africa CDC have welcomed the move, emphasizing a community-led response approach.
Here's the key detail: Ervebo is licensed specifically for Zaire ebolavirus, not the Bundibugyo strain. Early lab and animal data hint at possible cross-protection, but human evidence is lacking — which is exactly why 20,000 of the doses are earmarked for a Phase 3 clinical trial. The remaining 50,000 will go to frontline and health workers under current SAGE recommendations, with informed consent required given the uncertainty.
By the Numbers:
Why it matters: This deployment is a rare real-world scenario where a vaccine is being used — and simultaneously studied — against a related but distinct pathogen. The trial results could reshape future outbreak response protocols and vaccine policy across Africa.
